RSU1 and central nervous system cancer: Hence, patients with elevated RSU-1 expression would be expected to have aggressive gliomas and would benefit from a treatment that includes blocking RSU-1 whereas patients with reduced RSU-1 expression would be expected to have less aggressive tumors and would thus benefit from a conventional treatment.